Arnaud is co-founder, CEO and chief scientific officer at Aurion. Before Aurion, Arnaud spent 12 years at Novartis where he directed cell and gene therapy programs and built iPSC, CAR-T and ophthalmology cell therapy platforms. At Novartis, Arnaud and his team were responsible for advancing clinical candidates from early discovery to clinical stages. Prior to Novartis, Arnaud was the director of Rockefeller University’s stem cell facility, and co-founder and chief scientific officer of Inseron, which developed genetic biomarkers for drug discovery and pathway profiling. Arnaud holds an MBA from Boston University, a PhD in Life Sciences from the Université Pierre et Marie Curie (Paris VI), and an undergraduate degree from the University of Bordeaux.